Contents hide 1 Non-Small Cell Lung Cancer 2 Dosage Modifications 2.1 Dose reductions 2.1.1 90 mg/day dose 2.1.2 180 mg/day dose Brigatinib is a targeted cancer drug treatment for non small cell lung cancer (NSCLC). It is also known as Alunbrig. It is a treatment for a type of lung cancer called non small cell lung cancer (NSCLC) that has spread to other parts of the body (advanced or metastatic NSCLC). Non-Small Cell Lung Cancer Indicated for anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) 90 mg PO qDay for the first 7 days; if 90 mg/day tolerated, increase … Continue reading Beigani (Brigatinib)